Personalis Secures CE-IVD Marking for Blood Collection Kits, Expanding EU Clinical Trial Support
Event summary
- Personalis' EDTA Blood Collection Kit and cfDNA Blood Collection Kit received Class A CE-IVD marking under the EU's In Vitro Diagnostic Regulation (IVDR).
- The certification enables use of these kits in interventional clinical trials across the European Union and Great Britain.
- The kits are designed to maintain sample integrity for high-performance genomic analysis, including the company’s NeXT Personal MRD testing.
- CEO Chris Hall emphasized the milestone as a step toward supporting large-scale, global clinical trials.
The big picture
The CE-IVD marking positions Personalis to better support global biopharma partners in clinical trials, addressing a critical need for standardized pre-analytical sample collection. This aligns with the broader industry shift toward more sensitive and reliable genomic testing for precision oncology, particularly in detecting minimal residual disease (MRD). The certification could enhance Personalis' competitive edge in a market increasingly focused on regulatory-compliant, high-performance genomic solutions.
What we're watching
- Regulatory Expansion
- How quickly Personalis can secure similar approvals in other key markets beyond the EU and Great Britain.
- Biopharma Partnerships
- Whether the CE-IVD marking accelerates adoption by global biopharma companies for their clinical trials.
- Competitive Positioning
- The pace at which competitors in precision oncology develop comparable regulatory-approved specimen collection solutions.
Related topics